机译:在1/2临床试验中,通过单剂量的Chadox1 NcoV-19(AZD1222)疫苗引起的T细胞和抗体应答。
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Nuffield Department of Medicine University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Kennedy Institute of Rheumatology University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Nuffield Department of Medicine University of Oxford;
Clinical Biomanufacturing Facility Nuffield Department of Medicine University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
Clinical Biomanufacturing Facility Nuffield Department of Medicine University of Oxford;
The Jenner Institute University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
The Jenner Institute University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
Clinical Biomanufacturing Facility Nuffield Department of Medicine University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
The Jenner Institute University of Oxford;
Oxford Vaccine Group Department of Paediatrics University of Oxford;
The Jenner Institute University of Oxford;
机译:单剂量给药和增强剂量的影响对Chadox1 NcoV-19(AZD1222)疫苗的免疫原性和功效:四种随机试验的合并分析
机译:单剂量给药和增强剂量的影响对Chadox1 NcoV-19(AZD1222)疫苗的免疫原性和功效:四种随机试验的合并分析(Vol 397,PG 881,2021)
机译:SARS-COV-2疫苗的第1/2期试验,具有增强剂剂量的SARS-COV-2疫苗Chadox1 NCoV-19诱导多功能抗体反应。
机译:寄生虫诱导的B细胞凋亡导致损失特异性保护性抗锥虫组抗体反应,以及废除疫苗诱导的保护性记忆反应。
机译:疫苗诱导的母体抗体转移和对兔模型中婴儿免疫应答的影响的评价
机译:在先前感染SARS-COV-2的医疗保健工人的单剂量Chadox1 Ncov-19疫苗后抗体应答
机译:作者校正:在1/2临床试验中由单剂量的Chadox1 NcoV-19(AZD1222)疫苗诱导的T细胞和抗体应答
机译:Vaxfectin(注册商标)增强抗体和体外T细胞对5基因恶性疟原虫质粒DNa疫苗混合物各组分的低剂量反应